The Relationship Of The Medication Compliance With The Quality Of Life Of Type 2 Diabetes Mellitus Patients With Gangrene Complications: Hubungan Tingkat Kepatuhan Minum Obat terhadap Kualitas Hidup Pasien Diabetes Mellitus Tipe 2 dengan Komplikasi Gangren

Wulan Dwi Jumadi; Primanitha Ria  Utami; Irma  Susanti

doi:10.53342/pharmasci.v11i1.495

Authors

Wulan Dwi Jumadi Universitas Muhammadiyah Lamongan
Primanitha Ria Utami Universitas Muhammadiyah Lamongan
Irma Susanti Universitas Muhammadiyah Lamongan

DOI:

https://doi.org/10.53342/pharmasci.v11i1.495

Keywords:

Diabetes,, Gangren,, Kepatuhan,, Kualitas Hidup,, MARS-10,, WHOQOL-BREF,

Abstract

Diabetes Mellitus (DM) type 2 is a serious and chronic disease characterized by high blood glucose levels. DM causes complications such as gangrene. The success of DM management is influenced by factors, patient compliance in taking medication, which can ultimately reduce morbidity and mortality and improve the patient's quality of life. This study aims to identify the relationship between medication adherence and the quality of life of type 2 DM patients with gangrene complications. Sampling was carried out using purposive sampling and there were 95 type 2 DM patients with gangrene at the Sahabat Sehat Karanggeneng Clinic. Respondents with type 2 diabetes mellitus had high compliance with taking medication, reaching 93% and the lowest compliance with taking medication, reaching 7%. Respondents with type 2 diabetes mellitus had a moderate quality of life, namely 10.52%, good 62.01% and very good, namely 27.47%. This research uses a non-experimental cross-sectional study method. Spearman-rank test was used to analyze the data. The research instrument used the MARS-10 questionnaire for medication adherence and Whoqol-Bref for quality of life. The results of the Spearman-rank p-value test were p=0.001. There is a significant relationship between adherence to taking medication and the quality of life of type 2 DM patients with gangrene complications. Effective management of type 2 DM and prevention of gangrene complications are very important to improve compliance and maintain patient quality of life.

References

1) N. B. Gelaw et al., “Development and validation of risk prediction model for diabetic neuropathy among diabetes mellitus patients at selected referral hospitals, in Amhara regional state Northwest Ethiopia, 2005–2021,” PLoS One, vol. 18, no. 8 August, pp. 1–30, 2023, doi: https://10.1371/journal.pone.0276472.

2) J. Li, Z. Dong, X. Wang, X. Wang, L. Wang, and S. Pang, “Risk Factors for Diabetic Retinopathy in Chinese Patients with Different Diabetes Duration: Association of C-Peptide and BUN/Cr Ratio with Type 2 Diabetic Retinopathy,” Int. J. Gen. Med., vol. Volume 16, no. September, pp. 4027–4037, 2023, doi: https://10.2147/ijgm.s420983.

3) J. N. Nduati, S. M. Gatimu, and Y. Kombe, “Diabetic Foot Risk Assessment among Patients with Type 2 Diabetes in Kenya,” East African Heal. Res. J., vol. 6, no. 2, pp. 196–202, 2022, doi: https://10.24248/eahrj.v6i2.698.

4) Y. E. D. Ghilari, A. Iskandar, B. S. Wiratama, and A. B. Hartopo, “Joint Effect of Diabetes Mellitus and Hypertension on COVID-19 in-Hospital Mortality Stratified by Age Group and Other Comorbidities: A Cohort Retrospective Study Using Hospital-Based Data in Sleman, Yogyakarta,” Healthc., vol. 10, no. 10, 2022, doi: https://10.3390/healthcare10102103.

5) A. R. Dewi, “Profil Kesehatan 2021,” Tunas Agraria, vol. 3, no. 3. pp. 1–47, 2020.

6) P. Farmaki, C. Damaskos, N. Garmpis, A. Garmpi, S. Savvanis, and E. Diamantis, “Complications of the Type 2 Diabetes Mellitus,” Curr. Cardiol. Rev., vol. 16, no. 4, pp. 249–251, 2021, doi: https://10.2174/1573403x1604201229115531.

7) I. Romadhona, F. Herawati, and R. Yulia, “Profil Penggunaan Antibiotik dan Peta Kuman pada Pasien Gangren Diabetes Melitus di Sebuah RSUD di Kabupaten Gresik,” vol. 3, no. 2406, 2020.

8) F. Ratna Wati, “Hubungan Kepatuhan Konsumsi Obat Terhadap Kualitas Hidup Pasien Hipertensi Dengan Penyerta Diabetes Mellitus,” Media Husada J. Nurs. Sci., vol. 2, no. 2, pp. 28–34, 2021, doi: https://10.33475/mhjns.v2i2.46.

9) L. Musnelina, W. Mutiara, and A. Rianti, “Pengukuran Kualitas Hidup Pasien Diabetes Melitus Tipe 2 dengan Penyakit Penyerta Hipertensi Menggunakan SF-36,” Sainstech Farma, vol. 14, no. 2, pp. 63– 69, 2021, doi: https://10.37277/sfj.v14i2.832.

10) S. A. AlSadrah, “Impaired quality of life and diabetic foot disease in Saudi patients with type 2 diabetes: A cross-sectional analysis,” SAGE Open Med., vol. 7, 2019, doi: https://10.1177/2050312119832092.

11) S. Aulya Fitriani, Noormartany, and A. Mauludin, “Hubungan Kepatuhan Konsumsi Obat Antidiabetik dengan Kualitas Hidup Pasien Diabetes Melitus Tipe 2 di Kabupaten Garut,” Bandung Conf. Ser. Med. Sci., vol. 2, no. 1, pp. 312–318, 2022, doi: https://10.29313/bcsms.v2i1.754.

12) R. Mishra et al., “Medication adherence and quality of life among type-2 diabetes mellitus patients in India,” World J. Diabetes, vol. 12, no. 10, pp. 1740–1749, 2021, doi: https://10.4239/wjd.v12.i10.1740.

13) A. Firdiawan, S. A. Kristina, T. M. Andayani, M. F. Klinik, F. Farmasi, and U. Gadjah, “Hubungan Kepatuhan Pengobatan Terhadap Outcome Klinik Pasien Diabetes Relationship of Medication

Adherence to Clinical Outcome in Patients Type 2 Diabetes with Medication Adherence Rating Scale- 5 ( MARS-5 ),” vol. 17, no. 1, pp. 22–28, 2021, doi: https://10.22146/farmaseutik.v17i1.48053.

14) A. Bakar, S. N. Qomariah, C. H. Santoso, M. P. Gustomi, Y. Syaful, and L. Fatmawa, “Factors the incidence of hypoglycemia in diabetes mellitus patients: A pilot study in the emergency room,” Enferm. Clin., vol. 30, no. 2019, pp. 46–49, 2020, doi: https://10.1016/j.enfcli.2019.11.020.

15) J. F. Higea, “Penilaian Kualitas Hidup Terkait Kesehatan Pasien Diabetes Melitus Tipe 2 Di Puskesmas,” vol. 14, no. 2, 2022.

16) D. E. Anggraini and S. R. Rahayu, “Higeia Journal of Public Health,” Higeia J. Public Heal. Res. Dev., vol. 1, no. 3, pp. 84–94, 2017.

17) P. R. Utami and Devi Ristian Octavia, “The Effect of Visual Media Education in the Management Therapy on the Level of Knowledge of Patients Diabetes Mellitus with Comorbid,” J. Info Kesehat., vol. 21, no. 3, pp. 468–478, 2023, doi: https://10.31965/infokes.vol21.iss3.961.

18) P. R. Utami and D. R. Octavia, “Study of potential interactions of oral antidiabetic drugs in patients with type 2 diabetes mellitus with comorbidities: A retrospective study,” Pharm. Educ., vol. 22, no. 2, pp. 200–206, 2022, doi: https://10.46542/pe.2022.222.200206.

19) Y. Rahmayanti and P. Karlina, “Kepatuhan Minum Obat Hipoglikemia Oral terhadap Kadar Gula Darah dan Kualitas Hidup Pasien Diabetes Mellitus Tipe II,” J. Aceh Med., vol. 1, no. 2, pp. 49–55, 2017.

20) A. F. Anshari, B. Ichsan, and Z. Cholisoh, “Hubungan Kepatuhan Minum Obat terhadap HbA1C dan Kualitas Hidup Pasien Diabetes di RSI Purwodadi,” JPSCR J. Pharm. Sci. Clin. Res., vol. 8, no. 3, p. 317, 2023, doi: https://10.20961/jpscr.v8i3.73753.

21) Nabilatus, “Pola Penggunaan Obat Antibiotik Pada Pasien Diabetes Melitus Tipe 2 Dengan Luka Gangrene Di Rumah Sakit Umum Daerah Dr Slamet Martodirdjo Pamekasan,” vol. I, pp. 9–12, 2019.

22) S. Ulfa and S. K. Muflihatin, “Hubungan Pengetahuan dengan kualitas hidup Penderita Diabetes Melitus Tipe 2 di wilayah kerja Puskesmas Pasundan Kota Samarinda,” Borneo Student Res., vol. 4, no. 1, pp. 1–9, 2022.

23) M. Villar et al., “Epidemiologic and clinical impact of acinetobacter baumannii colonization and infection: A reappraisal,” Med. (United States), vol. 93, no. 5, pp. 202–210, 2014, doi: https://10.1097/MD.0000000000000036.

24) M. H. Sormin and F. Tenrilemba, “Analisis Faktor Yang Berhubungan Dengan Risiko Diabetes Melitus Tipe 2 Di Uptd Puskesmas Tunggakjati Kecamatan Karawang Barat Tahun 2019,” J. Kesehatan. Masyarakat., vol. 3, no. 2, pp. 120–146, 2019.

25) M. Elhariri, D. Hamza, R. Elhelw, and S. M. Dorgham, “Extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa in camel in Egypt: Potential human hazard,” Ann. Clin. Microbiol. Antimicrob., vol. 16, no. 1, pp. 4–9, 2017, doi: https://10.1186/s12941-017-0197-x.

26) S. Santajit and N. Indrawattana, “Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens,” Biomed Res. Int., vol. 2016, 2016, doi: https://10.1155/2016/2475067.

27) Y. P. Sukmawan, “Metformin / Glimepiride and Metformin / Glibenclamide , Which is Better ?: A Systematic Review and Meta-Analysis,” 2018.